Platelet-rich plasma compositions and methods of preparation

Abstract

Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions, and the use of compositions containing platelet-rich plasma to accelerate or complete the differentiation of a cell line. Particularly, use of platelet-rich plasma in conjunction with cell differentiation.

1 .- 9 . (canceled) 
     
     
         10 . A composition comprising:
 cells from an individual, and   platelet-rich plasma (PRP) isolated from whole blood of the individual, wherein the cells of the individual are treated with the PRP to produce induced pluripotent stem (iPS) cells.   
     
     
         11 . The composition of  claim 10 , wherein the cells are fibroblast cells from skin tissue from the individual. 
     
     
         12 . The composition of  claim 10 , further comprising a growth factor selected from the group consisting of vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), plerixafor, sargramostim, γ-tocotrienol, vitamin E, ancestim and bone morphogenic growth factor to the individual. 
     
     
         13 . The composition of  claim 10 , wherein the whole blood is obtained from spleen or bone marrow. 
     
     
         14 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelets concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises at least one cell selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, adult stem cells, and progenitor cell lines. 
     
     
         15 . The composition of  claim 14 , wherein the adult stem cells comprise mesenchymal stem cells. 
     
     
         16 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises progenitor or precursor stem cell lines. 
     
     
         17 . The composition of  claim 16 , wherein the progenitor or precursor stem cell lines comprise mesenchymal stem precursor lines. 
     
     
         18 . The composition of  claim 10 , wherein the composition comprises the platelet-rich plasma comprising a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises CD34+ cells at a concentration 1-3×10 9  per liter to 100×10 9  per liter or higher. 
     
     
         19 . The composition of  claim 15 , wherein the composition comprises the platelet-rich plasma comprising a platelets in a concentration of 151,000/microliter to 7,000,000/microliter or higher and comprises stromal-derived factor-1 (SDF-1) in a concentration of 100 pg/ml to 5000 pg/ml. 
     
     
         20 . The composition of platelet rich plasma comprising the platelet rich plasma derived from induced pluripotent stem cells at a platelet concentration of 151,000/microliter to 7,000,000/microliter or higher and pluripotent stem cells in any concentration or form. 
     
     
         21 . A method of differentiating cancer cells comprising:
 exposing the cancer cells to an isolated platelet-rich plasma (PRP) composition, wherein the isolated PRP composition comprises platelets at a concentration of 151,000/microliter to 7,000,000 per microliter;   thereby differentiating the cancer cells to a more mature phenotype.   
     
     
         22 . The method of  claim 21 , wherein the cancer cells comprise glioblastoma cells. 
     
     
         23 . The method of  claim 21 , wherein the platelets and cancer cells are from the same individual. 
     
     
         24 . The method of  claim 21 , wherein the isolated PRP composition is isolated from whole blood of an individual. 
     
     
         25 . The method of  claim 24 , wherein the whole blood is obtained from spleen or bone marrow.